Conditions · Pancreatic cancer
Pancreatic cancer frontier treatment options
KRAS-targeted agents, vaccine programs and DDR-directed therapy each publish specific mutation requirements. Matching against them narrows hundreds of listings to the handful worth calling.
Prefer to look first? Browse the live map without signing up.
Open options now (1151 open studies; showing 30)
- TRIALPHASE1NOT_YET_RECRUITING
Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
NP137 — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC
SHR-1701 · Apatinib · gemcitabine — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
AGEN2373 · Balstilimab · Cyclophosphamide — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer
Samuraciclib + Gemcitabine & Nab-Paclitaxel — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
JAB-23E73 · JAB-23E73 — 32 sites
- TRIALNANOT_YET_RECRUITING
PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT
collection of blood and tumor samples
- TRIALNARECRUITING
RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer
Blood sample — 1 site
- TRIALNANOT_YET_RECRUITING
Feasibility of the Loop Brush EUS-FNA for Characterization of Pancreatic Cysts: Pilot Clinical Investigation
Loop Brush Fine Needle Aspiration — 1 site
- TRIALPHASE3RECRUITING
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate · nab-paclitaxel; gemcitabine — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
EGFR FPBMC — 1 site
- TRIALNANOT_YET_RECRUITING
Personalised Nutritional Care in Older Patients With Pancreatic Ductal Adenocarcinoma
Experimental: Personalised nutritional care delivered by a trained dietitian — 5 sites
- TRIALPHASE2RECRUITING
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Zanidatamab — 28 sites
- TRIALPHASE2RECRUITING
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
Bupivacaine · Hydromorphone · Iopamidol — 1 site
- TRIALPHASE3RECRUITING
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
Immuncell-LC · Gemcitabine — 1 site
- TRIALPHASE2RECRUITING
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Riluzole · Placebo — 1 site
- TRIALNARECRUITING
Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors
Total Pancreatectomy with Islet Autotransplantation (TPIAT) — 1 site
- TRIALPHASE1RECRUITING
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
ASP2138 · Pembrolizumab · Oxaliplatin — 46 sites
- TRIALPHASE1 / PHASE2RECRUITING
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VMD-928 100 mg Tablet · VMD-928 Tablet and Pembrolizumab (200 mg) — 15 sites
- TRIALPHASE3RECRUITING
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound
Auricular point stimulation plus dexamethasone · Standard pharmacologic antiemetic regimen — 1 site
- TRIALPHASE1RECRUITING
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
ELI-002 7P · Tislelizumab · mFOLFIRINOX — 7 sites
- TRIALNARECRUITING
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
68Ga-SorB PET/CT — 1 site
- EXPANDED ACCESSAVAILABLE
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
DNG64-CAR-V — 1 site
- TRIALNARECRUITING
Impact of Non-magnetic Screen Respiratory Self-guidance During MRI-guided Radiotherapy Sessions for Mobile Lesions
With non-magnetic screen — 1 site
- TRIALNARECRUITING
A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy
Physical Activity and Nutritional Recommendations and Support — 1 site
- TRIALPHASE1RECRUITING
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
KST-6051 — 9 sites
- TRIALNARECRUITING
Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
Claudin18.2 CAR-T cells — 1 site
- TRIALNARECRUITING
The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy
HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy — 1 site
- TRIALNARECRUITING
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence
Treatment Plan — 1 site
- TRIALNARECRUITING
Increasing Germline Genetic Testing for Patients With Cancer
Implementation strategies — 10 sites
- TRIALPHASE2RECRUITING
Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
pH-NASOX-Immune Group — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Narrow by phase or treatment type
By state in the United States
By country
Each country page filters the live registry to listed sites in that country and links to the relevant official national or regional registry for additional local discovery.
Common questions
- How does Trial0 find Pancreatic cancer options?
- Every list on this page is a live query of ClinicalTrials.gov (API v2) for open interventional trials and expanded-access programs, refreshed at most hourly. Nothing is hand-curated or cached beyond that window.
- Does a match mean the patient is eligible?
- No. Structured registry fields (age, sex, status, phase) give firm matched/not-matched states; free-text criteria can only be checked for mentions, which are signposts to verify with the site. Only the trial site can determine actual eligibility.
- What does the verified site data mean?
- Registry recruiting status is often stale. Trial0 separately records first-hand observations — whether a specific site is really recruiting and whether the investigator accepts outside referrals — each stamped with the date it was verified.
- What does access help cost?
- The eligibility map and new-trial alerts are free. Pro is $49/month or £49/month and covers contact research, draft preparation and approval-first outreach. Trial0 never takes a commission from a provider.
How to use this Pancreatic cancer trial page
This page is refreshed from live registry data and shows currently open interventional studies and expanded-access programmes. Trial records are leads, not a clinical recommendation.
Use the full matcher to add age, treatment history, biomarkers and a location. It labels published criteria honestly: a mention in free text is a prompt to verify, not a finding of eligibility.
Free alerts help you notice new registry entries. Pro can research a contact and prepare outreach, but Trial0 asks for approval before contacting each trial.
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Data refreshed at most every 1 hour(s).